Specialists in quantifying the current and future burden of non-communicable and rare genetic diseases.
Our data-driven epidemiology generates evidence to support strategic planning and portfolio management at each stage of the drug development process, helping to bring new therapies to patients faster.
From molecule to market, our solutions can help.
Deep expertise in disease epidemiology combined with entrepreneurial vision. Our work has been widely published and peer-reviewed by world-leading experts.
Why Us?We’ve spent over a decade developing our methodology to help you ask the right questions and make the best decisions.
SolutionsWe’ve answered all kinds of questions for many different organisations, covering over 25 NCDs and rare genetic diseases in over 80 countries.
Track RecordOur experienced and multidisciplinary team brings together epidemiologists, geneticists, mathematicians, data scientists, researchers, and software engineers.
About UsHealthLumen was recently commissioned by Movember, one of the leading charities changing the face of men’s health, to quantify the economic impact of men’s poor health for their ‘Real Face of Men’s Health’ 2024 UK Report. The study found that in 2023 the five diseases that cause the largest number of years of life lost […]
ReadHealthLumen has recently conducted a genetic database analysis study in partnership with Rallybio, a clinical-stage biotechnology company, focused on understanding the proportions of women at higher risk for Foetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) across a broad population of diverse ancestries. The results demonstrated that the proportion of women at higher risk for FNAIT was […]
ReadAwareness of the vast impact of rare diseases, which affect approximately 300 million people globally (1), has significantly increased over the years, leading to increased funding and investment in rare disease research and therapy development. Although more than half of the novel drug approvals by the FDA’s Center for Drug Evaluation and Research last […]
ReadIn partnership with AstraZeneca, HealthLumen has recently published two publications that project the clinical (1) and economic (2) burden of Chronic Kidney Disease (CKD) and Kidney Replacement Therapy (KRT) into the future, as part of the “Inside CKD” programme, which contributes to the major strategic initiative at AstraZeneca dedicated to driving better patient outcomes. From […]
Read